Delivery Order SPE2DB24D1104-SPE2DB25FYFA5
- Not listed
- The Defense Logistics Agency awarded a $34,787.81 delivery order to AmerisourceBergen Drug Corp on July 24, 2025, for the supply of Biktarvy 50-200-25 mg tablets (30-count units). This is a firm fixed-price, competitively awarded contract with no set-aside designation and an ultimate completion date of July 25, 2025. The contract is performed from AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a $35,074.07 firm fixed price delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for the supply of Biktarvy 50-200-25 mg tablets in quantities of 30 units. The contract is non-set-aside and competitively awarded, with an ultimate completion date of August 13, 2025. Performance will occur at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under the company's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order valued at $11,499.73 to AmerisourceBergen Drug Corp for Biktarvy 50-200-25 mg tablets (quantity 30) on August 19, 2025, with an ultimate completion date of August 20, 2025. The contract employs firm fixed pricing with no set-aside designation, indicating competitive award. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as the place of performance. This delivery order represents a child contract under...
- The Defense Logistics Agency awarded a delivery order valued at $26,362.04 to AmerisourceBergen Drug Corp on August 27, 2025, for the supply of Biktarvy 50-200-25 mg tablets (30-count units). This is a firm fixed price, competitively awarded contract with no set-aside designation and an ultimate completion date of August 28, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a $33,897.39 delivery order to AmerisourceBergen Drug Corp on August 19, 2025, for the supply of Biktarvy 50-200-25 mg tablets (30-count units). This firm fixed-price, non-set-aside contract represents a single delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical, valued at $999,999,999.00 through December 2026. The contract will be performed at AmerisourceBergen's facility in Conshohocken,...
- The Defense Logistics Agency (DLA) Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 28, 2025, for the supply of Biktarvy 50-200-25 mg tablets in quantities of 30 units. This is a firm fixed-price delivery order with a ceiling value of $55,124.14 and an ultimate completion date of August 29, 2025. The contract involves no set-aside designation, indicating it was competitively awarded. The place of performance is AmerisourceBergen's corporate office location...
- The Defense Logistics Agency awarded a delivery order valued at $18,577.92 to AmerisourceBergen Drug Corp for the supply of Biktarvy 50-200-25 mg tablets (30-count units) with a firm fixed price structure. This non-competitive delivery order is set to be completed by August 25, 2025, and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The pharmaceutical product will be delivered to the company's distribution hub in...
- The Defense Logistics Agency awarded a delivery order valued at $12,495.58 to AmerisourceBergen Drug Corp for Biktarvy 50-200-25 mg tablets (30-count units) on August 25, 2025, with completion scheduled for August 26, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and specifies performance at AmerisourceBergen's Conshohocken, Pennsylvania facility. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a firm fixed-price delivery order valued at $26,946.22 for Biktarvy 50-200-25 mg tablets (30-count unit of use packaging) with an ultimate completion date of August 19, 2025. This non-set-aside competitive award was issued on August 18, 2025, with performance to be fulfilled at AmerisourceBergen's Conshohocken, Pennsylvania location. The delivery order falls under AmerisourceBergen's existing Indefinite Delivery Contract (SPE2DX)...
- The Defense Logistics Agency awarded a $27,224.33 delivery order to AmerisourceBergen Drug Corp on August 22, 2025, for the supply of Biktarvy 50-200-25 mg tablets (30-count units). This firm fixed-price delivery order, with an ultimate completion date of August 25, 2025, represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999.99 million through December 2026. The award was competitively awarded with...
- SPE2DB24D1104Indefinite Delivery Contract
- SPE2DB24D1104-SPE2DB25FYFA5Delivery Order
The Defense Logistics Agency awarded a $40,059.56 delivery order to AmerisourceBergen Drug Corp on August 27, 2025, for the supply of Biktarvy 50-200-25 mg tablets in quantities of 30 units. This is a firm fixed price, competitively awarded contract with an ultimate completion date of August 28, 2025. The contract is classified as a child award under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, a $999,999,999.00 prime vendor agreement running through December 2026. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving federal medical procurement needs for military and veteran healthcare systems. This delivery order is executed under AmerisourceBergen's comprehensive global pharmaceutical support vehicle with the DLA, which enables the company to supply a wide range of pharmaceutical products and medical supplies to support military healthcare programs worldwide. The Biktarvy tablets are an antiretroviral medication for HIV treatment, reflecting the company's portfolio of specialty medications and brand-name drugs across multiple therapeutic domains. No set-aside designation was applied to this award, indicating it was awarded through open competition. The contract represents one of numerous delivery orders fulfilling federal medical supply requirements through the company's established relationship with the Defense Logistics Agency.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $40.1k | 8/27/25 |